Chimerix, Inc. (CMRX)
| Market Cap | 539.06M |
| Revenue (ttm) | 4.56M |
| Net Income (ttm) | -138.26M |
| Shares Out | 86.23M |
| EPS (ttm) | -1.90 |
| PE Ratio | n/a |
| Forward PE | 256.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 838,367 |
| Open | 6.20 |
| Previous Close | 6.35 |
| Day's Range | 6.05 - 6.35 |
| 52-Week Range | 2.43 - 11.57 |
| Beta | 1.59 |
| Analysts | Buy |
| Price Target | 17.67 (+182.3%) |
| Est. Earnings Date | Nov 4, 2021 |
About CMRX
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 ...
Financial Performance
In 2020, Chimerix's revenue was $5.37 million, a decrease of -57.09% compared to the previous year's $12.52 million. Losses were -$43.52 million, -61.34% less than in 2019.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for Chimerix stock is "Buy." The 12-month stock price forecast is 17.67, which is an increase of 182.27% from the latest price.
News
Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference
DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...
Chimerix to Present at 2021 Wedbush PacGrow Healthcare Conference
DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today...
Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021
DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today...
Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox
– First smallpox antiviral approved for all age groups, including infants, and patients who have difficulty swallowing – – First smallpox antiviral approved for all age groups, including infants, and pa...
Chimerix Announces Upcoming Presentations at the American Society of Clinical Oncology 2021 Annual Meeting
DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today ...
Chimerix Reports First Quarter 2021 Financial Results and Provides Operational Update
– BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 –
Chimerix (CMRX) Sees Hammer Chart Pattern: Time to Buy?
Chimerix (CMRX) has been struggling lately, but the selling pressure may be coming to an end soon
Chimerix to Report First Quarter 2021 Financial Results and Provide an Operational Update on May 6, 2021
DURHAM, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...
Chimerix Appoints Vicki Vakiener to Board of Directors
DURHAM, N.C., April 26, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...
Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...
5 Small-Cap Biotech Stocks Trading Under $10 With Massive Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference
DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...
Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Re...
WESTON, Fla., Feb. 26, 2021 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of inflammatory lung disease...
Chimerix's DSTAT Shows Promising Results In First Cohort Of COVID-19 Study
Chimerix Inc (NASDAQ: CMRX) reports topline results from the first cohort (n=12) of its Phase 2/3 study evaluating DSTAT in hospitalized patients with Acute Lung Injury (ALI) and COVID-19 infection. The...
Steven Cohen Dives Into Chimerix
Billionaire investor Steven Cohen (Trades, Portfolio), who leads Point72 Asset Management, disclosed a 5.37% stake in Chimerix Inc. (NASDAQ:CMRX) earlier this week.
Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
DURHAM, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases...
Chimerix Announces Pricing of Public Offering of Common Stock
DURHAM, N.C., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases...
Chimerix Announces Proposed $75,000,000 Public Offering of Common Stock
DURHAM, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases...
Why Chimerix Stock Skyrocketed on Friday
A new acquisition could be quite the shot in the arm for the company.
Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma
Chimerx's (CMRX) NDA for Brincidofovir Accepted by FDA
Chimerix's (CMRX) NDA for brincidofovir as a medical countermeasure for smallpox has been accepted by the FDA.
Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
FDA Grants Priority Review and Sets PDUFA Date for April 7, 2021 FDA Grants Priority Review and Sets PDUFA Date for April 7, 2021
Chimerix, Inc. (CMRX) CEO Michael Sherman on Q3 2020 Results - Earnings Call Transcript
Chimerix, Inc. (CMRX) CEO Michael Sherman on Q3 2020 Results - Earnings Call Transcript
Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference
DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today...
Chimerix to Report Third Quarter 2020 Financial Results and Provide an Operational Update on November 5, 2020
DURHAM, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today...